Literature DB >> 710175

The effect of pentoxifylline on the flow properties of human blood.

A M Ehrly.   

Abstract

Recent investigations have revealed that erythrocytes from patients with chronic arterial occlusive disease are significantly less deformable than red blood cells from healthy subjects. The influence of pentoxifylline on red blood cell fluidity was measured by a standard filtration technique using 8 micron membrane filters. Impaired deformability of erythrocytes was significantly improved in patients suffering from peripheral vascular disorders following intravenous injection of 200 mg pentoxifylline. Studies on reduced red cell deformability induced by hyperosmolarity in vitro showed that pentoxifylline (4 and 20 microgram/ml) produced a dose-dependent improvement both in blood from healthy subjects and from patients with peripheral arterial occlusive disease. The results suggest that the positive therapeutic effect of pentoxifylline in peripheral arterial occlusive disease is mediated by improving red cell fluidity in the microcirculation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 710175     DOI: 10.1185/03007997809110195

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  Pentoxifylline in arterial disease of the legs.

Authors:  R Verhaeghe; M Verstraete
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  The effect of pentoxifylline on filterability of normal red blood cells and their adhesiveness to cultured endothelial cells.

Authors:  S O Sowemimo-Coker; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Transiently hypoxic tumour cell turnover and radiation sensitivity in human tumour xenografts.

Authors:  Brennan J Wadsworth; Che-Min Lee; Kevin L Bennewith
Journal:  Br J Cancer       Date:  2022-01-14       Impact factor: 9.075

4.  Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.

Authors:  B A Teicher; T S Herman; J Tanaka; B Dezube; A Pardee; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 5.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.

Authors:  A Ward; S P Clissold
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

Review 6.  Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.

Authors:  J E Frampton; R N Brogden
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.